Dissolution incompatibility of paracetamol as a silent dissolution retardent of concomitantly administered drugs

Show simple item record

dc.contributor.author Yasarathna, Kithmini
dc.contributor.author Wijesinghe, Chamodi
dc.contributor.author Jayasuriya, Banukie
dc.contributor.author Pathirana, Walisinghe
dc.date.accessioned 2023-01-10T09:53:40Z
dc.date.available 2023-01-10T09:53:40Z
dc.date.issued 2016-12-22
dc.identifier.citation Yasarathna, K., Wijesinghe, C., Jayasuriya, B., & Pathirana, W. (2017). Dissolution Incompatibility of Paracetamol as a Silent Dissolution Retardent Of Concomitantly Administered Drugs. en_US
dc.identifier.issn 2249-1848
dc.identifier.uri http://ir.lib.ruh.ac.lk/xmlui/handle/iruor/10129
dc.description.abstract High strength tablets containing 500 mg or more active ingredients could affect the dissolution of concomitantly administered drugs. Dissolution of ten generic solid dosage forms was determined in the presence of sodium bicarbonate and paracetamol, 500 – 2250 mg. In a total of 111 dissolution tests 41 failed (37%) to meet the criteria. Where paracetamol was present 36 out of 50 end points failed (72%) with an extreme case in diltiazem tablets with 0% dissolution. Since longest test end points with failures mostly range from 60 – 90 minutes it is advisable to administer paracetamol 1.5 hours after other drugs in order to avoid potential pharmacokinetic disturbances. en_US
dc.language.iso en en_US
dc.publisher Pharma Scholars Library en_US
dc.subject Dissolution incompatibility en_US
dc.subject paracetamol en_US
dc.subject sodium bicarbonate en_US
dc.subject diltiazem en_US
dc.title Dissolution incompatibility of paracetamol as a silent dissolution retardent of concomitantly administered drugs en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account